Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70799 | 0.88 | HRH3 (0.46) | CHRM4HRH3SMN1; SMN2HSD11B1GNAO1 | |
| Hydrochloric Acid SCHEMBL30330895 | 0.86 | HRH3 (0.45) | CHRM4HRH3SMN1; SMN2HSD11B1GNAO1 | |
| SCHEMBL8278983 | 0.86 | OPRL1 (0.50) | OPRL1OPRM1OPRK1HRH3 | |
| Fluoride SCHEMBL29252579 | 0.86 | HRH3 (0.45) | CHRM4HRH3SMN1; SMN2HSD11B1GNAO1 | |
| SCHEMBL25856473 | 0.84 | KMT2A (0.46) | OPRL1OPRM1KMT2ACHRM4HRH3 | |
| SCHEMBL10648639 | 0.84 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL10648643 | 0.84 | OPRL1 (0.53) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL26042799 | 0.82 | OPRL1 (0.46) | OPRL1OPRM1OPRK1HRH3GNAO1 | |
| SCHEMBL21120664 | 0.82 | OPRL1 (0.48) | OPRL1OPRM1OPRK1HRH3 | |
| SCHEMBL12513458 | 0.82 | OPRL1 (0.51) | OPRL1OPRM1OPRK1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | FOGHORN THERAPEUTICS INC. (US) | 2023-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767330-B2 | Citrate salt, pharmaceutical compositions, and methods of making and using the same | CS, SMARCC2, SMARCC1 | OPRL1 4859/4885OPRM1 4873/4885KMT2A 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.